中牧股份(600195.SH):調整2019年度利潤分配預案 每10股派現0.9447元
格隆匯5月19日丨中牧股份(600195.SH)公佈,公司按照現金分紅總額、資本公積金轉增股本總額不變的原則,對2019年度利潤分配預案的每股現金分紅金額、每股轉增股本數量進行相應調整。公司2019年度利潤分配預案為:每股現金紅利0.09447元(含税),利潤分配總額為80,028,237.42元(本次利潤分配總額差異系每股現金紅利的尾數四捨五入調整所致),佔公司2019年歸屬於上市公司股東淨利潤的比例約為31.32%;每股轉增股本數量為0.198886股(保留小數點後六位,具體股數以權益分派實施完畢後中國證券登記結算有限責任公司上海分公司確認的股數為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.